Ask about this productRelated genes to: CD51 antibody
- Gene:
- ITGAV NIH gene
- Name:
- integrin subunit alpha V
- Previous symbol:
- VNRA, MSK8, VTNR
- Synonyms:
- CD51
- Chromosome:
- 2q32.1
- Locus Type:
- gene with protein product
- Date approved:
- 1988-07-19
- Date modifiied:
- 2016-10-05
Related products to: CD51 antibody
Related articles to: CD51 antibody
- Spinal cord injury (SCI) leads to fibrotic scarring that blocks axonal regeneration, yet the molecular mechanisms controlling scar formation remain incompletely understood. Microglia and fibroblasts accumulate at lesion sites, but their intercellular communication, spatial organization and therapeutic tractability have not been systematically mapped. - Source: PubMed
Publication date: 2026/09/11
Chen LiwenWang SiqiaoXiao ZhihuiZhao ShitongFan Wenyong - Hepatocyte ballooning is a defining histological marker of progressive steatohepatitis, but its molecular basis remains poorly defined. - Source: PubMed
Publication date: 2026/09/12
Ganguly DebopriyoMondal BandanaDas SubhasDey IndrashishMandal AyanGhosh TrinathDeo MonalishaAhmed MisbaBanerjee SomaChatterjee AnkitaBasu Priyadarshi - Lymph node (LN) metastasis is a major determinant of prognosis in gastric cancer, yet the immune microenvironment of metastatic versus non-metastatic nodes remains incompletely defined. Spatial resolution of tumor-immune interactions may clarify mechanisms of immune escape associated with nodal progression. We performed compartment-resolved spatial transcriptomic profiling to characterize immune gene expression in gastric cancer LNs. Forty-seven formalin-fixed paraffin-embedded LNs from 13 patients with T2-T4, M0 gastric adenocarcinoma (N1-2: n = 7; N3: n = 6) were analyzed using the NanoString GeoMx Digital Spatial Profiler and an 84-gene immune pathways panel. Twenty-nine non-metastatic and 18 metastatic LNs were profiled. Regions of interest were segmented into tumor and immune compartments, yielding 65 spatially defined compartments. Differential expression was assessed across three comparisons: metastatic versus non-metastatic LNs; metastatic LNs from N1-2 versus N3 patients; and non-metastatic LNs from N1-2 versus N3 patients. Within the immune compartments, non-metastatic LNs showed higher expression of T-cell activation and checkpoint genes (CD3E, CD27, PDCD1, CTLA4), consistent with preserved immune surveillance. Metastatic LNs were enriched for WNT signaling and adhesion-related genes (CTNNB1, ITGAV) and epithelial markers (EPCAM), indicating tumor-driven immune remodeling. N3 metastatic LNs demonstrated increased ICOSLG, IL6, and IFNGR1 expression, suggesting chronic inflammatory activation and immune dysfunction. Notably, non-metastatic LNs from N3 patients upregulated antigen-presentation genes (CD74, HLA-DRB), consistent with early immune conditioning. No significant differences emerged in tumor compartments or pseudo-bulk analyses. Spatial transcriptomic profiling reveals nodal burden-associated immune remodeling, and identifies candidate biomarkers and therapeutic targets for precision immunotherapy in gastric cancer. - Source: PubMed
Publication date: 2026/09/17
Suwatthanarak ThanawatNampoolsuksan ChawisaTanjak PariyadaThanormjit KullanistAcharayothin OnchiraChaiboonchoe AmphunSuwatthanarak TharathornPithukpakorn ManopChalermwai Wipapat VickiSwangsri JirawatMethasate AsadaChinswangwatanakul VitoonParakonthun Thammawat - Despite multiple clinical trials, disease-modifying treatments for COPD are currently limited. Since many drugs target proteins, identifying causality between proteins and lung function informs understanding of COPD pathophysiology and may suggest novel targets. We used Mendelian randomisation (MR) to prioritise proteins as potentially causal for imparied lung function. For prioritised proteins, we explored their potential suitability as drug targets by predicting their effects on a range of clinical outcomes. - Source: PubMed
Publication date: 2026/09/01
Chen JingShrine NickColey KayeshaPacker Richard JEdris AhmedIzquierdo Abril GLim BrandonLee MikyeongDudbridge FrankWalters Robin GHall Ian PWain Louise VTobin Martin DGuyatt Anna L - Atherosclerotic cardiovascular disease (ASCVD), including coronary heart disease (CHD), ischemic stroke (IS), and peripheral artery disease (PAD), represents a growing global health burden. Integrins have emerged as potential biomarkers and therapeutic targets. This study aimed to explore the role of integrins as biomarkers for ASCVD and to identify potential drug targets. A total of 33,210 UK Biobank participants were included. Cox proportional hazards models were used to assess associations between circulating integrin levels and ASCVD and its subtypes. Mendelian randomization and colocalization analyses were performed to investigate potential causal relationships and shared genetic variants underlying integrin levels and disease risk. During a median follow-up of 14.04 years, 2468 participants developed ASCVD. In subtype-specific analyses, 1541 CHD events, 1050 IS events, and 590 PAD events were identified. In observational analyses, ITGA11, ITGA2, ITGAM, ITGAV, ITGB1 and ITGB2 were associated with lower ASCVD risk, whereas ITGA5 and ITGBL1 were associated with higher risk. For ASCVD mortality, ITGA11, ITGAM, ITGAV, and ITGB2 showed protective associations, while ITGAX and ITGB6 were linked to increased risk. Sex-stratified analyses revealed distinct patterns, including male-specific risk associations for ITGAX and ITGBL1 and a female-specific protective association for ITGB2. Mendelian randomization supported causal associations for five integrins, with ITGA11 showing consistency with observational findings. Colocalization analysis suggested shared causal variants between ITGAV and both CHD and IS. This study provides both observational and genetic evidence for the critical role of integrins in ASCVD, implicating their potential for assessing disease risk and serving as candidate therapeutic targets. - Source: PubMed
Publication date: 2026/08/15
Niu MengyingFeng YuyaoShu KeqiangYang YixuanChen JunyeLai ZhichaoLiu BaoPeng Bin